Fig. 3: Mutation profiling of intrahepatic cholangiocarcinoma (iCCA) cohort.
From: Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary
a Oncoplot of number, type and frequency of mutations by patient as reported by Foundation Medicine, actionable mutations highlighted in red box. Greyed out if mutation profiling unavailable; ^subclonal mutation. *patient underwent local molecular profiling rather than Foundation Medicine assay. b Reasons for mutation profiling failure by patient. White = successful profiling, Grey = unsuccessful. ARID1A AT-rich interaction domain 1 A, BICC bicaudal C Homolog 1, BRAF proto-oncogene B-raf, CCND2 cyclin D2, CDH1 cadherin 1, FGFR fibroblast growth factor receptor, IDH isocitrate dehydrogenase, KDM5A lysine demethylase 5 A, KDM6A lysine demethylase 6 A, MRE11A MRE11 Homolog, Double Strand Break Repair Nuclease, MYC MYC proto-oncogene, NF2 neurofibromin 2, P14ARF cyclin dependent kinase inhibitor 2 A, P16INK4a cyclin dependent kinase inhibitor 2 A, PGFRA platelet-derived growth factor receptor alpha, RICTOR RPTOR independent companion of MTOR Complex 2, TGFBR2 transforming growth factor beta receptor 2; TMB tumour mutation burden.
